Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure

Frontiers in Cardiovascular Medicine

Volumn 2, Issue , 2015, Pages

  Parry, Traci L ^a   Melehani, Jason H ^a   Ranek, Mark J ^b   Willis, Monte S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

functional amyloid; inflammasome; necrosome; pharmacological chaperones; signalosome

Indexed keywords

EID: 84999726077     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2015.00025     Document Type: Article

References (105)

1. Guan J, Mishra S, Falk RH, Liao R. Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol (2012) 302:H544–52.10.1152/ajpheart.00815.201122058156
2. Kirshenblat Ia D, Serbeniuk VN. [The effect of the nervous system on the sensitivity of rat ovaries to lactogenic hormone]. Probl Endokrinol Gormonoter (1966) 12:100–5.
3. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med (1997) 337:898–909.10.1056/NEJM199709253371306
4. Klein AL, Hatle LK, Burstow DJ, Seward JB, Kyle RA, Bailey KR, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol (1989) 13:1017–26.10.1016/0735-1097(89)90254-42647814
5. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart (1997) 78:74–82.10.1136/hrt.78.1.749290406
6. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res (2004) 94:1008–10.10.1161/01.RES.0000126569.75419.7415044325
7. Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, et al. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol (2010) 145:67–8.10.1016/j.ijcard.2009.04.04419446898
8. Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol (2011) 301:H2305–12.10.1152/ajpheart.00503.201121963839
9. Sikkink LA, Ramirez-Alvarado M. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis (2010) 1:e98.10.1038/cddis.2010.7521368874
10. Gianni D, Li A, Tesco G, McKay KM, Moore J, Raygor K, et al. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation (2010) 121:1216–26.10.1161/CIRCULATIONAHA.109.87951020194882
11. Subramanian K, Gianni D, Balla C, Assenza GE, Joshi M, Semigran MJ, et al. Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy. J Am Coll Cardiol (2015) 65:1199–214.10.1016/j.jacc.2015.01.03125814227
12. Maloney MT, Bamburg JR. Cofilin-mediated neurodegeneration in Alzheimer’s disease and other amyloidopathies. Mol Neurobiol (2007) 35:21–44.10.1007/BF0270062217519504
13. Munsie LN, Truant R. The role of the cofilin-actin rod stress response in neurodegenerative diseases uncovers potential new drug targets. Bioarchitecture (2012) 2:204–8.10.4161/bioa.2254923267414
14. Christians ES, Mustafi SB, Benjamin IJ. Chaperones and cardiac misfolding protein diseases. Curr Protein Pept Sci (2014) 15:189–204.10.2174/138920371566614033111151824694370
15. Mehta A, Sequiera GL, Ramachandra CJ, Sudibyo Y, Chung Y, Sheng J, et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res (2014) 102:497–506.10.1093/cvr/cvu06024623279
16. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation (2006) 113:365–73.10.1161/CIRCULATIONAHA.105.57020016432067
17. Braakman I, Bulleid NJ. Protein folding and modification in the mammalian endoplasmic reticulum. Annu Rev Biochem (2011) 80:71–99.10.1146/annurev-biochem-062209-09383621495850
18. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem (2006) 75:333–66.10.1146/annurev.biochem.75.101304.12390116756495
19. Gregersen N, Bross P, Vang S, Christensen JH. Protein misfolding and human disease. Annu Rev Genomics Hum Genet (2006) 7:103–24.10.1146/annurev.genom.7.080505.11573716722804
20. Gomes CM. Protein misfolding in disease and small molecule therapies. Curr Top Med Chem (2012) 12:2460–9.10.2174/156802661121222000223339300
21. Dobson CM. The generic nature of protein folding and misfolding. In: Uversky VN, Fink AL, editors. Protein Misfolding, Aggregation, and Conformational Diseases. New York: Springer (2006). p. 21–41.
22. Dill KA, Chan HS. From Levinthal to pathways to funnels. Nat Struct Biol (1997) 4:10–9.10.1038/nsb0197-108989315
23. Onuchic JN, Wolynes PG. Theory of protein folding. Curr Opin Struct Biol (2004) 14:70–5.10.1016/j.sbi.2004.01.009
24. Thirumalai D, O’Brien EP, Morrison G, Hyeon C. Theoretical perspectives on protein folding. Annu Rev Biophys (2010) 39:159–83.10.1146/annurev-biophys-051309-103835
25. Han JH, Batey S, Nickson AA, Teichmann SA, Clarke J. The folding and evolution of multidomain proteins. Nat Rev Mol Cell Biol (2007) 8:319–30.10.1038/nrm214417356578
26. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med (2004) 10(Suppl):S10–7.10.1038/nm106615272267
27. Ross CA, Poirier MA. Opinion: what is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol (2005) 6:891–8.10.1038/nrm174216167052
28. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A, et al. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci USA (2004) 101:10132–6.10.1073/pnas.040190010115220483
29. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res (2003) 92:715–24.10.1161/01.RES.0000067471.95890.5C12649263
30. Tannous P, Zhu H, Nemchenko A, Berry JM, Johnstone JL, Shelton JM, et al. Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation (2008) 117:3070–8.10.1161/CIRCULATIONAHA.107.76387018541737
31. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation (2008) 117:2743–51.10.1161/CIRCULATIONAHA.107.75023218490523
32. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B, et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem (2001) 276:30057–63.10.1074/jbc.M10014220011375979
33. Tian Z, Zheng H, Li J, Li Y, Su H, Wang X. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res (2012) 111:532–42.10.1161/CIRCRESAHA.112.27098322740087
34. Willis MS, Patterson C. Hold me tight: role of the heat shock protein family of chaperones in cardiac disease. Circulation (2010) 122:1740–51.10.1161/CIRCULATIONAHA.110.942250
35. Zhang H, Rajasekaran NS, Orosz A, Xiao X, Rechsteiner M, Benjamin IJ. Selective degradation of aggregate-prone CryAB mutants by HSPB1 is mediated by ubiquitin-proteasome pathways. J Mol Cell Cardiol (2010) 49:918–30.10.1016/j.yjmcc.2010.09.00420863832
36. Sanbe A, Daicho T, Mizutani R, Endo T, Miyauchi N, Yamauchi J, et al. Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy. PLoS One (2009) 4:e5351.10.1371/journal.pone.000535119399179
37. Morello JP, Petaja-Repo UE, Bichet DG, Bouvier M. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci (2000) 21:466–9.10.1016/S0165-6147(00)01575-311121835
38. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest (2000) 105:887–95.10.1172/JCI868810749568
39. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 98:2729–38.10.1172/JCI1190988981918
40. Leandro P, Gomes CM. Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev Med Chem (2008) 8:901–11.10.2174/13895570878513278318691147
41. Saraiva MJ, Magalhaes J, Ferreira N, Almeida MR. Transthyretin deposition in familial amyloidotic polyneuropathy. Curr Med Chem (2012) 19:2304–11.10.2174/09298671280026923622471982
42. Obici L, Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs (2014) 23:1239–51.10.1517/13543784.2014.92254125003808
43. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 421:185–203.10.1016/j.jmb.2011.12.06022244854
44. Johnson SM, Connelly S, Wilson IA, Kelly JW. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem (2008) 51:260–70.10.1021/jm070873518095641
45. Razavi H, Palaninathan SK, Powers ET, Wiseman RL, Purkey HE, Mohamedmohaideen NN, et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl (2003) 42:2758–61.10.1002/anie.200351179
46. Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 260:2802–14.10.1007/s00415-013-7051-723974642
47. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 79:785–92.10.1212/WNL.0b013e3182661eb122843282
48. Scott LJ. Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs (2014) 74:1371–8.10.1007/s40265-014-0260-225022953
49. Klamerus KJ, Watsky E, Moller R, Wang R, Riley S. The effect of tafamidis on the QT interval in healthy subjects. Br J Clin Pharmacol (2014).10.1111/bcp.1256125546001
50. Alhamadsheh MM, Connelly S, Cho A, Reixach N, Powers ET, Pan DW, et al. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 3:97ra81.10.1126/scitranslmed.3002473
51. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4’-iodo-4’-deoxydoxorubicin. Blood (1995) 86:855–61.7620181
52. Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, et al. Interaction of the anthracycline 4’-iodo-4’-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA (1995) 92:2959–63.10.1073/pnas.92.7.29597708755
53. Cardoso I, Merlini G, Saraiva MJ. 4’-iodo-4’-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J (2003) 17:803–9.10.1096/fj.02-0764com12724338
54. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J (2006) 20:234–9.10.1096/fj.05-4509com16449795
55. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta (2008) 1782:517–22.10.1016/j.bbadis.2008.05.00518572024
56. Hyung SJ, DeToma AS, Brender JR, Lee S, Vivekanandan S, Kochi A, et al. Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-beta species. Proc Natl Acad Sci USA (2013) 110:3743–8.10.1073/pnas.122032611023426629
57. Lopez del Amo JM, Fink U, Dasari M, Grelle G, Wanker EE, Bieschke J, et al. Structural properties of EGCG-induced, nontoxic Alzheimer’s disease abeta oligomers. J Mol Biol (2012) 421:517–24.10.1016/j.jmb.2012.01.01322300765
58. Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol (2012) 101:805–13.10.1007/s00392-012-0463-z22584381
59. Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci (2010) 41:219–25.10.1016/j.ejps.2010.06.010
60. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol (2009) 65:331–41.10.1007/s00228-008-0610-719198822
61. Pullakhandam R, Srinivas PN, Nair MK, Reddy GB. Binding and stabilization of transthyretin by curcumin. Arch Biochem Biophys (2009) 485:115–9.10.1016/j.abb.2009.02.01319268650
62. Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett (2011) 585:2424–30.10.1016/j.febslet.2011.06.03021740906
63. Ferreira N, Santos SA, Domingues MR, Saraiva MJ, Almeida MR. Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochim Biophys Acta (2013) 1832:39–45.10.1016/j.bbadis.2012.10.00723069388
64. Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. Nat Rev Neurosci (2014) 15:84–97.10.1038/nrn3638
65. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol (2013) 13:397–411.10.1038/nri3452
66. Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity (2013) 39:432–41.10.1016/j.immuni.2013.08.03724054327
67. Cai X, Chen J, Xu H, Liu S, Jiang QX, Halfmann R, et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell (2014) 156:1207–22.10.1016/j.cell.2014.01.06324630723
68. Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol (2014) 15:727–37.10.1038/ni.291324952505
69. Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell (2014) 156:1193–206.10.1016/j.cell.2014.02.00824630722
70. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 355:581–92.10.1056/NEJMoa05513716899778
71. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 360:2416–25.10.1056/NEJMoa081078719494217
72. Sutinen EM, Pirttila T, Anderson G, Salminen A, Ojala JO. Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-beta production in human neuron-like cells. J Neuroinflammation (2012) 9:199.10.1186/1742-2094-9-19922898493
73. van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med (2005) 5:87–98.10.1007/s10238-005-0071-6
74. Ha SJ, Kim WS, Hwang SJ, Woo JS, Shon IS, Bae JH, et al. A case of systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. J Am Soc Echocardiogr (2009) 22(542):e545–7.10.1016/j.echo.2009.01.022
75. Isabel C, Georgin-Lavialle S, Aouba A, Delarue R, Nochy D, Karras A, et al. [Cardiac amyloidosis: a case series of 14 patients, description and prognosis]. Rev Med Interne (2013) 34:671–8.10.1016/j.revmed.2013.05.00324090573
76. Matsui M, Okayama S, Tsushima H, Samejima K, Kanki T, Hasegawa A, et al. Therapeutic benefits of tocilizumab vary in different organs of a patient with AA amyloidosis. Case Rep Nephrol (2014) 2014:823093.10.1155/2014/82309325197587
77. Simons JP, Al-Shawi R, Ellmerich S, Speck I, Aslam S, Hutchinson WL, et al. Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci USA (2013) 110:16115–20.10.1073/pnas.130662111023959890
78. Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid (2008) 15:262–8.10.1080/1350612080252467619065298
79. Hattori Y, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid (2012) 19:37–40.10.3109/13506129.2011.63646022260742
80. Wada Y, Kobayashi D, Murakami S, Oda M, Hanawa H, Kuroda T, et al. Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents. Scand J Rheumatol (2011) 40:402–4.10.3109/03009742.2011.569754
81. Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, et al. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol (2011) 187:64–73.10.4049/jimmunol.110050021622869
82. Hafner-Bratkovic I, Bencina M, Fitzgerald KA, Golenbock D, Jerala R. NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1beta and neuronal toxicity. Cell Mol Life Sci (2012) 69:4215–28.10.1007/s00018-012-1140-022926439
83. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 9:857–65.10.1038/ni.163618604209
84. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol (2010) 11:897–904.10.1038/ni.193520835230
85. Niemi K, Teirila L, Lappalainen J, Rajamaki K, Baumann MH, Oorni K, et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol (2011) 186:6119–28.10.4049/jimmunol.100284321508263
86. Rapsinski GJ, Wynosky-Dolfi MA, Oppong GO, Tursi SA, Wilson RP, Brodsky IE, et al. Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infect Immun (2015) 83:693–701.10.1128/IAI.02370-1425422268
87. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell (1998) 93:215–28.10.1016/S0092-8674(00)81573-19568714
88. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol (2013) 98:462–72.10.1113/expphysiol.2012.06833822848083
89. Luo B, Wang F, Li B, Dong Z, Liu X, Zhang C, et al. Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy. Clin Chem Lab Med (2013) 51:1521–8.10.1515/cclm-2012-060023382313
90. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 27:1309–18.10.1097/00003246-199907000-0001810446825
91. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation (2008) 117:2662–9.10.1161/CIRCULATIONAHA.107.73187718474811
92. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 162:597–605.10.1016/j.ahj.2011.06.01221982649
93. Furukawa Y, Nukina N. Functional diversity of protein fibrillar aggregates from physiology to RNA granules to neurodegenerative diseases. Biochim Biophys Acta (2013) 1832:1271–8.10.1016/j.bbadis.2013.04.01123597596
94. Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell (2012) 150:339–50.10.1016/j.cell.2012.06.01922817896
95. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M, et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res (2014) 103:206–16.10.1093/cvr/cvu14624920296
96. Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA, et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol (2012) 107:270.10.1007/s00395-012-0270-822553001
97. Moriwaki K, Chan FK. Necrosis-dependent and independent signaling of the RIP kinases in inflammation. Cytokine Growth Factor Rev (2014) 25:167–74.10.1016/j.cytogfr.2013.12.01324412261
98. Kandala S, Kim IM, Su H. Neddylation and deneddylation in cardiac biology. Am J Cardiovasc Dis (2014) 4:140–58.25628956
99. Wei N, Chamovitz DA, Deng XW. Arabidopsis COP9 is a component of a novel signaling complex mediating light control of development. Cell (1994) 78:117–24.10.1016/0092-8674(94)90578-98033203
100. Wei N, Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol (2003) 19:261–86.10.1146/annurev.cellbio.19.111301.112449
101. Lingaraju GM, Bunker RD, Cavadini S, Hess D, Hassiepen U, Renatus M, et al. Crystal structure of the human COP9 signalosome. Nature (2014) 512:161–5.10.1038/nature13566
102. Su H, Li F, Ranek MJ, Wei N, Wang X. COP9 signalosome regulates autophagosome maturation. Circulation (2011) 124:2117–28.10.1161/CIRCULATIONAHA.111.04893421986281
103. Su H, Li J, Osinska H, Li F, Robbins J, Liu J, et al. The COP9 signalosome is required for autophagy, proteasome-mediated proteolysis, and cardiomyocyte survival in adult mice. Circ Heart Fail (2013) 6:1049–57.10.1161/CIRCHEARTFAILURE.113.00033823873473
104. Enchev RI, Schreiber A, Beuron F, Morris EP. Structural insights into the COP9 signalosome and its common architecture with the 26S proteasome lid and eIF3. Structure (2010) 18:518–27.10.1016/j.str.2010.02.00820399188
105. Huang X, Hetfeld BK, Seifert U, Kähne T, Kloetzel PM, Naumann M, et al. Consequences of COP9 signalosome and 26S proteasome interaction. FEBS J (2005) 272:3909–17.10.1111/j.1742-4658.2005.04807.x16045761